[go: up one dir, main page]

ECSP12012160A - Compuesto heterociclico - Google Patents

Compuesto heterociclico

Info

Publication number
ECSP12012160A
ECSP12012160A ECSP12012160A ECSP12012160A EC SP12012160 A ECSP12012160 A EC SP12012160A EC SP12012160 A ECSP12012160 A EC SP12012160A EC SP12012160 A ECSP12012160 A EC SP12012160A
Authority
EC
Ecuador
Prior art keywords
compound
heterociclical
salt
useful
cancer
Prior art date
Application number
Other languages
English (en)
Inventor
Misaki Homma
Toru Miyazaki
Yuya Oguro
Osamu Kurasawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012160(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP12012160A publication Critical patent/ECSP12012160A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto útil como un agente profiláctico o terapéutico para cáncer. Se describe específicamente un compuesto representado por la fórmula (I) (en donde cada símbolo es como se define en la descripción) o una sal del mismo, o un promedicamento del compuesto o la sal del mismo, el cual es útil para la prevención o tratamiento de cáncer.
ECSP12012160 2010-02-17 2012-09-17 Compuesto heterociclico ECSP12012160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010031899 2010-02-17
JP2010131950 2010-06-09

Publications (1)

Publication Number Publication Date
ECSP12012160A true ECSP12012160A (es) 2013-03-28

Family

ID=44482985

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012160 ECSP12012160A (es) 2010-02-17 2012-09-17 Compuesto heterociclico

Country Status (37)

Country Link
US (6) US8722660B2 (es)
EP (2) EP3533797B1 (es)
JP (1) JP5689454B2 (es)
KR (1) KR101735868B1 (es)
CN (1) CN102844320B (es)
AU (1) AU2011216404B2 (es)
BR (1) BR112012020311B1 (es)
CA (1) CA2790284C (es)
CL (1) CL2012002250A1 (es)
CO (1) CO6592104A2 (es)
CR (1) CR20120448A (es)
CY (1) CY1121792T1 (es)
DK (1) DK2540728T3 (es)
DO (1) DOP2012000224A (es)
EA (1) EA020724B1 (es)
EC (1) ECSP12012160A (es)
ES (1) ES2733221T3 (es)
GE (1) GEP20146202B (es)
HR (1) HRP20190947T1 (es)
HU (1) HUE043514T2 (es)
IL (1) IL221442A0 (es)
LT (1) LT2540728T (es)
MA (1) MA34064B1 (es)
ME (1) ME03410B (es)
MX (1) MX353500B (es)
MY (1) MY164776A (es)
NZ (1) NZ602089A (es)
PE (1) PE20130184A1 (es)
PH (1) PH12012501650B1 (es)
PL (1) PL2540728T3 (es)
PT (1) PT2540728T (es)
RS (1) RS58796B1 (es)
SG (1) SG183304A1 (es)
SI (1) SI2540728T1 (es)
SM (1) SMT201900385T1 (es)
TN (1) TN2012000401A1 (es)
WO (1) WO2011102399A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187795A1 (en) * 2010-08-11 2013-03-28 Millennium Pharm Inc Heteroaryls and uses thereof
EP3100742B1 (en) 2014-01-31 2020-05-20 Carna Biosciences Inc. Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor
TW201620879A (zh) 2014-04-28 2016-06-16 杜邦股份有限公司 除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) * 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
CA3105722C (en) 2015-12-07 2022-10-11 Zymergen Inc. Microbial strain improvement by a htp genomic engineering platform
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
ES2884398T3 (es) * 2016-03-28 2021-12-10 Takeda Pharmaceuticals Co Formas cristalinas de 2-[(2s)-1-azabiciclo[2.2.2]oct-2-il]-6-(3-metil-1H-pirazol-4-il)tieno[3,2-d]pirimidin-4(3H)-ona hemihidrato
EA035560B1 (ru) * 2016-07-28 2020-07-07 Такеда Фармасьютикал Компани Лимитед Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
EP3538523B1 (en) 2016-11-08 2021-05-19 Cancer Research Technology Limited Pyrimidinone derivatives as cdc7 inhibitors
US11155879B2 (en) * 2017-03-01 2021-10-26 Takeda Pharmaceutical Company Limited Method of predicting effects of CDC7 inhibitor
CN112409373A (zh) * 2017-05-21 2021-02-26 南京正济医药研究有限公司 作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US11524957B2 (en) * 2018-04-02 2022-12-13 Takeda Pharmaceutical Company Limited Process for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one
TWI846703B (zh) 2018-06-19 2024-07-01 日商武田藥品工業股份有限公司 癌症治療方法
IL280130B2 (en) * 2018-07-19 2024-11-01 Takeda Pharmaceuticals Co Pharmaceutical compositions with a cdc7 inhibitor
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR20220027883A (ko) * 2019-05-30 2022-03-08 치아타이 티안큉 파마수티컬 그룹 주식회사 Cdc7 억제제로서의 테트라사이클릭 화합물
CN114126621A (zh) * 2019-07-19 2022-03-01 武田药品工业株式会社 用于癌症治疗的组合疗法
JP2022546294A (ja) * 2019-08-20 2022-11-04 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｃｄｃ７阻害剤として使用される四環式化合物
EP4069369A4 (en) * 2019-12-06 2024-02-14 Schrödinger, Inc. CYCLIC COMPOUNDS AND METHODS OF USE THEREOF
JP2023541047A (ja) * 2020-09-10 2023-09-27 シュレーディンガー， インコーポレイテッド がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
EP4253388A1 (en) * 2020-11-30 2023-10-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salt form used as cdc7 inhibitor and crystal form thereof
CN112661770B (zh) * 2020-12-24 2022-11-08 南京正济医药研究有限公司 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
WO2022167999A1 (en) 2021-02-08 2022-08-11 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法
EP4416156A1 (en) * 2021-10-13 2024-08-21 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
WO2025160538A1 (en) * 2024-01-26 2025-07-31 The Board Of Regents Of The University Of Texas System Compositions and methods for treating hair graying and loss associated with aging
WO2025168620A1 (en) 2024-02-07 2025-08-14 Bayer Aktiengesellschaft Heteroaryl-substituted 4,5-dihydro-1h-2,4,5-oxadiazines as novel fungicides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
EP1329454A1 (en) 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
JP2005538118A (ja) 2002-08-06 2005-12-15 アストラゼネカ アクチボラグ Ｔｉｅ２（ｔｅｋ）活性を持つ縮合したピリジン及びピリミジン
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
ES2324536T7 (es) * 2003-06-11 2012-03-16 Xention Limited Derivados de tenopirimidina como inhibidores de los canales de potasio.
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2005014572A1 (en) 2003-08-08 2005-02-17 Pharmacia Italia S.P.A. Pyrimidylpyrrole derivatives active as kinase inhibitors
CA2561977A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
WO2006078574A2 (en) 2005-01-19 2006-07-27 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1907398A1 (en) 2005-07-15 2008-04-09 AstraZeneca AB Therapeutic agents
KR101149954B1 (ko) 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) * 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007102679A1 (en) 2006-03-06 2007-09-13 Je Il Pharmaceutical Co., Ltd. Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
US20090030196A1 (en) * 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
CA2728674A1 (en) 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis methods of use thereof
US8691828B2 (en) 2009-03-05 2014-04-08 Takeda Pharmaceutical Company Limited Thienopyrimidine as CDC7 kinase inhibitors
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CN102481294A (zh) 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids

Also Published As

Publication number Publication date
HUE043514T2 (hu) 2019-08-28
SMT201900385T1 (it) 2019-09-09
PT2540728T (pt) 2019-07-11
JP5689454B2 (ja) 2015-03-25
US20140228352A1 (en) 2014-08-14
EP2540728A1 (en) 2013-01-02
TN2012000401A1 (en) 2014-01-30
KR101735868B1 (ko) 2017-05-15
GEP20146202B (en) 2014-11-25
EP2540728A4 (en) 2013-11-06
US8722660B2 (en) 2014-05-13
HRP20190947T1 (hr) 2019-07-26
AU2011216404A1 (en) 2012-09-20
CO6592104A2 (es) 2013-01-02
MX353500B (es) 2018-01-16
DK2540728T3 (da) 2019-05-13
US8933069B2 (en) 2015-01-13
CL2012002250A1 (es) 2013-02-08
US20140235615A1 (en) 2014-08-21
BR112012020311A2 (pt) 2017-03-01
CA2790284C (en) 2019-01-08
EA020724B1 (ru) 2015-01-30
EP2540728B1 (en) 2019-04-10
US20130029969A1 (en) 2013-01-31
IL221442A0 (en) 2012-10-31
US9388195B2 (en) 2016-07-12
US20150158882A1 (en) 2015-06-11
MA34064B1 (fr) 2013-03-05
PE20130184A1 (es) 2013-03-09
PL2540728T3 (pl) 2019-09-30
RS58796B1 (sr) 2019-07-31
US9655900B2 (en) 2017-05-23
US20170209452A1 (en) 2017-07-27
PH12012501650A1 (en) 2012-10-22
CA2790284A1 (en) 2011-08-25
MY164776A (en) 2018-01-30
US8921354B2 (en) 2014-12-30
JPWO2011102399A1 (ja) 2013-06-17
SG183304A1 (en) 2012-09-27
SI2540728T1 (sl) 2019-06-28
KR20130001246A (ko) 2013-01-03
PH12012501650B1 (en) 2018-11-07
CN102844320B (zh) 2016-03-23
CY1121792T1 (el) 2020-07-31
EP3533797A1 (en) 2019-09-04
ES2733221T3 (es) 2019-11-28
EP3533797B1 (en) 2023-12-20
NZ602089A (en) 2014-05-30
AU2011216404B2 (en) 2016-04-07
MX2012009602A (es) 2012-12-17
ME03410B (me) 2020-01-20
EA201290800A1 (ru) 2013-03-29
LT2540728T (lt) 2019-06-25
US20160310494A1 (en) 2016-10-27
WO2011102399A1 (ja) 2011-08-25
CR20120448A (es) 2012-11-13
DOP2012000224A (es) 2013-01-31
BR112012020311B1 (pt) 2019-01-29
CN102844320A (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
ECSP12012160A (es) Compuesto heterociclico
MX2013006113A (es) Compuestos biciclico.
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
EA201400178A1 (ru) Лечение рака молочной железы
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
EA201171367A1 (ru) Винилиндазолильные соединения
SI3725810T1 (sl) Kombinacijska terapija, ki vključuje protitelesa proti klavdinu 18.2 za zdravljenje raka
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
CL2019000844A1 (es) Compuesto de piridina.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX373786B (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer.
TWD161529S (zh) 治療燈
ECSP10010526A (es) Compuesto heterociclico
MX361499B (es) Baricitinib deuterado.
CR20140537A (es) Compuesto heterocíclico nitrogenado
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201591024A1 (ru) Димерные соединения
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
EP4268891A3 (en) Compound for use in methods for treatment of polycystic kidney disease
PH12015500399A1 (en) Azaindolines
EA201491581A1 (ru) Везикулярные композиции
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии